Profil
Nate Demars is Vice President & Head-Clinical Operations at Aktis Oncology, Inc. since 2024.
Former roles include Senior Director-Clinical Operations at Alaunos Therapeutics, Inc. and Senior Director-Clinical Operations at Neogene Therapeutics, Inc. Education includes graduate studies at the University of Connecticut and undergraduate studies at the University of New Hampshire.
Aktive Positionen von Nate Demars
| Unternehmen | Position | Beginn |
|---|---|---|
| AKTIS ONCOLOGY, INC. | Corporate Officer/Principal | 01.09.2024 |
Ehemalige bekannte Positionen von Nate Demars
| Unternehmen | Position | Ende |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that provides TCR therapies targeting neo-antigens in solid cancers | Corporate Officer/Principal | - |
Ausbildung von Nate Demars
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
University of Connecticut
University of Connecticut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of New Hampshire
University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that provides TCR therapies targeting neo-antigens in solid cancers | Health Technology |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers radiopharmaceuticals to treat tumor cancers | Health Technology |
















